Proteolytic Degradation Is a Major Contributor to Bioprosthetic Heart Valve Failure

Background Whereas the risk factors for structural valve degeneration (SVD) of glutaraldehyde‐treated bioprosthetic heart valves (BHVs) are well studied, those responsible for the failure of BHVs fixed with alternative next‐generation chemicals remain largely unknown. This study aimed to investigate the reasons behind the development of SVD in ethylene glycol diglycidyl ether–treated BHVs. Methods and Results Ten ethylene glycol diglycidyl ether–treated BHVs excised because of SVD, and 5 calcified aortic valves (AVs) replaced with BHVs because of calcific AV disease were collected and their proteomic profile was deciphered. Then, BHVs and AVs were interrogated for immune cell infiltration, microbial contamination, distribution of matrix‐degrading enzymes and their tissue inhibitors, lipid deposition, and calcification. In contrast with dysfunctional AVs, failing BHVs suffered from complement‐driven neutrophil invasion, excessive proteolysis, unwanted coagulation, and lipid deposition. Neutrophil infiltration was triggered by an asymptomatic bacterial colonization of the prosthetic tissue. Neutrophil elastase, myeloblastin/proteinase 3, cathepsin G, and matrix metalloproteinases (MMPs; neutrophil‐derived MMP‐8 and plasma‐derived MMP‐9), were significantly overexpressed, while tissue inhibitors of metalloproteinases 1/2 were downregulated in the BHVs as compared with AVs, together indicative of unbalanced proteolysis in the failing BHVs. As opposed to other proteases, MMP‐9 was mostly expressed in the disorganized prosthetic extracellular matrix, suggesting plasma‐derived proteases as the primary culprit of SVD in ethylene glycol diglycidyl ether–treated BHVs. Hence, hemodynamic stress and progressive accumulation of proteases led to the extracellular matrix degeneration and dystrophic calcification, ultimately resulting in SVD. Conclusions Neutrophil‐ and plasma‐derived proteases are responsible for the loss of BHV mechanical competence and need to be thwarted to prevent SVD.

[1]  A. Kutikhin,et al.  Early Postoperative Immunothrombosis of Bioprosthetic Mitral Valve and Left Atrium: A Case Report , 2022, International journal of molecular sciences.

[2]  Yunbing Wang,et al.  A PEGylation method of fabricating bioprosthetic heart valves based on glutaraldehyde and 2-amino-4-pentenoic acid co-crosslinking with improved antithrombogenicity and cytocompatibility. , 2022, Acta biomaterialia.

[3]  A. Kutikhin,et al.  EMbedding and Backscattered Scanning Electron Microscopy: A Detailed Protocol for the Whole-Specimen, High-Resolution Analysis of Cardiovascular Tissues , 2021, Frontiers in Cardiovascular Medicine.

[4]  E. V. Kuznetsova,et al.  Cross-linking method using pentaepoxide for improving bovine and porcine bioprosthetic pericardia: A multiparametric assessment study. , 2021, Materials science & engineering. C, Materials for biological applications.

[5]  A. Kutikhin,et al.  Ultrastructural Pathology of Atherosclerosis, Calcific Aortic Valve Disease, and Bioprosthetic Heart Valve Degeneration: Commonalities and Differences , 2020, International journal of molecular sciences.

[6]  K. Toutouzas,et al.  Aortic valve: anatomy and structure and the role of vasculature in the degenerative process , 2020, Acta cardiologica.

[7]  I. Zhuravleva,et al.  Diepoxy- Versus Glutaraldehyde-Treated Xenografts: Outcomes of Right Ventricular Outflow Tract Reconstruction in Children , 2020, World journal for pediatric & congenital heart surgery.

[8]  A. Kutikhin,et al.  Development of calcific aortic valve disease: Do we know enough for new clinical trials? , 2019, Journal of molecular and cellular cardiology.

[9]  G. Novo,et al.  Chronic inflammation: A key role in degeneration of bicuspid aortic valve. , 2019, Journal of molecular and cellular cardiology.

[10]  C. Lally,et al.  Collagen fibre orientation and dispersion govern ultimate tensile strength, stiffness and the fatigue performance of bovine pericardium. , 2019, Journal of the mechanical behavior of biomedical materials.

[11]  M. Ishihara,et al.  Mechanisms of aortic stenosis. , 2017, Journal of cardiology.

[12]  B. Prendergast,et al.  Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Societ , 2017, European heart journal.

[13]  Mevlüt Çelik,et al.  Mechanical versus bioprosthetic aortic valve replacement , 2017, European heart journal.

[14]  Jeroen J. Bax,et al.  Bioprosthetic Heart Valves, Thrombosis, Anticoagulation, and Imaging Surveillance. , 2017, JACC. Cardiovascular interventions.

[15]  M. Sacks,et al.  Fixation of Bovine Pericardium-Based Tissue Biomaterial with Irreversible Chemistry Improves Biochemical and Biomechanical Properties , 2017, Journal of Cardiovascular Translational Research.

[16]  David Ayares,et al.  Human antibody recognition of xenogeneic antigens (NeuGc and Gal) on porcine heart valves: could genetically modified pig heart valves reduce structural valve deterioration? , 2016, Xenotransplantation.

[17]  A. Bogachev-Prokophiev,et al.  Results of the Ross procedure in adults: a single-centre experience of 741 operations. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  O. Barbarash,et al.  Prosthetic heart valve selection in women of childbearing age with acquired heart disease: a case report , 2016, Journal of Medical Case Reports.

[19]  C. Otto,et al.  Calcific aortic stenosis , 2016, Nature Reviews Disease Primers.

[20]  Susanna Price,et al.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). , 2015, European heart journal.

[21]  David K. C. Cooper,et al.  Xenograft bioprosthetic heart valves: Past, present and future. , 2015, International journal of surgery.

[22]  O. Barbarash,et al.  Impact of recipient-related factors on structural dysfunction of xenoaortic bioprosthetic heart valves , 2015, Patient preference and adherence.

[23]  Jean-Paul Soulillou,et al.  Potential deleterious role of anti‐Neu5Gc antibodies in xenotransplantation , 2015, Xenotransplantation.

[24]  I. Alferiev,et al.  The susceptibility of bioprosthetic heart valve leaflets to oxidation. , 2014, Biomaterials.

[25]  U. Galili Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits , 2013, Immunology.

[26]  P. Pibarot,et al.  Improving assessment of aortic stenosis. , 2012, Journal of the American College of Cardiology.

[27]  M. Sacks,et al.  Neomycin enhances extracellular matrix stability of glutaraldehyde crosslinked bioprosthetic heart valves. , 2011, Journal of biomedical materials research. Part B, Applied biomaterials.

[28]  N. Vyavahare,et al.  Neomycin binding preserves extracellular matrix in bioprosthetic heart valves during in vitro cyclic fatigue and storage. , 2009, Acta biomaterialia.

[29]  Michael S Sacks,et al.  Stability and function of glycosaminoglycans in porcine bioprosthetic heart valves. , 2006, Biomaterials.

[30]  W. Klepetko,et al.  Alpha‐Gal on bioprostheses: xenograft immune response in cardiac surgery , 2005, European journal of clinical investigation.

[31]  M. Sacks,et al.  Response of heterograft heart valve biomaterials to moderate cyclic loading. , 2004, Journal of biomedical materials research. Part A.

[32]  Dan T Simionescu,et al.  Extracellular matrix degrading enzymes are active in porcine stentless aortic bioprosthetic heart valves. , 2003, Journal of biomedical materials research. Part A.

[33]  D. Simionescu,et al.  Glycosaminoglycan-degrading enzymes in porcine aortic heart valves: implications for bioprosthetic heart valve degeneration. , 2003, The Journal of heart valve disease.

[34]  S. Sellers,et al.  Platelets , 1958, JACC: Basic to Translational Science.

[35]  J. M. Lee,et al.  Stress state during fixation determines susceptibility to fatigue-linked biodegradation in bioprosthetic heart valve materials. , 2002, Biomedical sciences instrumentation.